The transplantation of fetal mesencephalic cell suspensions into the brain striatal system is an emerging treatment for Parkinson's disease. However, one objection to this procedure is the relatively poor survival of implanted cells. The ability of neurotrophic factors to regulate developmental neuron survival and differ entiation suggests they could be used to enhance the success of cerebral grafts. We studied the effects of neurotrophin-3 (NT-3) or glial cell line-derived neurotrophic factor (GDNF) on the survival of dopaminergic neurons from rat fetal ventral mesencephalic cells (FMCs) implanted into the rat striatum. Two conditions were tested: (a) incubation of FMCs in media containing NT-3 and GDNF, prior to grafting, and (b) cografting of FMCs with cells engineered to overexpress high levels of NT-3 or GDNF. One week after grafting into the rat striatum, the survival of TH+ neurons was significantly increased by pretreatment of ventral mesencephalic cells with NT-3 or GDNF. Similarly, co-graft of ventral mesencephalic cells with NT-3-or GDNF-overexpressing cells, but not the mock-transfected control cell line, increased the survival of graft-derived dopaminergic neurons. Interestingly, we also found that co-grafting of GDNF-overexpress ing cells was less effective than NT-3 at improving the survival of fetal dopaminergic neurons in the grafts, and that only GDNF induced intense TH immunostaining in fibers and nerve endings of the host tissue surrounding the implant. Thus, our results suggest that NT-3, by strongly enhancing survival, and GDNF, by promoting both survival and sprouting, may improve the efficiency of fetal transplants in the treatment of Parkinson's disease.
INTRODUCTION
Intrastriatal grafting of fetal mesencephalic cells (FMCs) containing dopaminergic neurons has been pro posed as treatment to alleviate dopaminergic cell loss in Parkinson's disease (10, 18, 23) . However, the low sur vival of the transplanted dopaminergic neurons (12) in dicates that this procedure should be considered with caution. The identification of growth factors that im prove the survival and activity of nigral dopaminergic neurons has suggested that these molecules may im prove the survival of transplanted FMCs (22) .
Here we focus on growth factors of two different families: the neurotrophins and the glial cell-line derived neurotrophic factor (GDNF) family. The neurotrophin family is formed by nerve growth factor (NGF), brainderived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), -4/5 (NT-4/5), and -6 (NT-6). They bind and activate two different types of receptor: a common p75 neurotrophin receptor, and a specific tyrosine kinase re ceptor: trkA for NGF, trkB for BDNF and NT-4/5, and trkC for NT-3 (28) .
The GDNF family of neurotrophic factors is formed by GDNF (37) , neurturin (NTN) (33) , persephin (PSP) (40) , and artemin (ART) (6) . Ligands of this family bind to high-affinity glycosylphosphatidylynolsitol (GPI)-anchored receptors, collectively named GDNF family re ceptor a (GFRa), to form a complex that subsequently tially bound by GDNF (31) , GFRa2 by NTN (31) , GFRa4 by PSP (16) , and GFRa3 by ART (6) .
A large number of growth factors stimulate the sur vival and differentiation of dopaminergic neurons in pri mary cultures. This includes members of the neuro trophin family, such as BDNF, NT-3, and NT-4 (26, 27, 35, 58) , and members of the GDNF family, such as GDNF (8, 14, 24, 37) , NTN (25) , PSP (40) , and ART (6) . In vivo, endogenous dopaminergic neurons also re spond to several of these factors, including the neuro trophins BDNF, NT-3, and NT-4 (2, 20, 35) , and GDNF (7) (8) (9) 11, 13, 45) . In addition, fetal dopaminergic neurons grafted into the rat striatum respond to BDNF (44, 59) , , and GDNF (3, 19, 43, 46, 48, 50, 51, 56) . Be cause of the peptidic nature of growth factors and the presence of extracellular peptidases and uptake systems, a steady production of neurotrophic factors is required. One procedure for the continuous administration of growth factors is to implant genetically modified stable cells that produce them. This strategy has shown that factors of the neurotrophin (4, 35) and GDNF families (1, 5) enhance the survival and differentiation of central catecholaminergic neurons in vivo.
Here we studied the effects of NT-3 and GDNF on fetal mesencephalic dopaminergic neurons grafted into the striatum. FMCs were either pretreated with NT-3 or GDNF prior to grafting or were co-grafted with stable cell lines overexpressing NT-3 or GDNF (1, 5) . Our re sults show that both GDNF and NT-3 treatments im proved the viability of fetal dopaminergic neurons in the graft.
MATERIALS AND METHODS

Animals and 6-Hydroxydopamine Lesions
Male Sprague-Dawley rats, weighing about 250 g, 
Preparation of Fetal Mesencephalic Cell (FMC) Suspensions
Cell suspensions were prepared from the ventral mes encephalon of 14-day-old embryos. The mesencephalic area was dissected out as described by Dunnett and Bjork lund (15) , incubated at 37°C for 20 min in Dulbecco's modified essential medium (DMEM) supplemented with 2 mM glutamine, containing 0.05% DNase and 0.1% trypsin. The cell suspensions were gently disagregated, washed in DMEM, and sedimented by centrifugation. Cells were resuspended in 5 ul of DMEM per piece and embryo (17) . The final concentration was adjusted to 100,000 cell/ul with DMEM. In some experiments, sus pensions of FMC were preincubated for 3 h with NT-3 or GDNF (both at 50 ng/ml, from RBI, Natick, MA) or in medium without neurotrophins. To evaluate the via bility of the cell suspensions, the percentage of surviving cells was determined by fluorescence microscopy with acridine/ethidium bromide (1:1), as described (15) .
Transfected Fibroblasts
Rat 3T3 fibroblasts (American Type Culture Collec tion, Manassas, VA) overexpressing NT-3 (4) or GDNF (5), and mock-transfected fibroblasts were used. Trans fected 3T3 cells were grown in DMEM supplemented with 10% fetal calf serum, 1 mg/ml penicillin/strepto mycin, 1 mg/ml glutamine, and 200 ug/ml G-418 at 37°C and 5% C0 2 . Cells in active growth phase were washed and collected in serum-free medium at a concen tration between 0.5 and 2.0 x 10 5 cells per microliter for grafting.
Grafting
Three weeks after the 6-OHDA lesion of the medial forebrain, animals were grafted with a suspension of fe tal mesencephalic cells introduced into the right striatum (coordinates A: +0.7, L: -3.2; H: -5, from bregma) with a flow rate of 1 ul/min, according to one of the follow ing procedures: a. 3 pi of suspensions containing about 400,000 FMC was implanted after preincubation for 3 h at 37°C in a shaking bath with or without NT-3 or GDNF (50 ng/ml in both cases). Animals were processed in all cases for the study of dopaminergic cell survival, 7 days after grafting, in or der to avoid excessive proliferation of the fibroblasts.
TH Immunocytochemistry
The animals were anesthetized and perfused transcardially with 4% paraformaldehyde in phosphate buffer. The brains were rapidly removed and postfixed for 24 h, and selected coronal sections were embedded in paraffin. Sections (5 pm) through the substantia nigra or the striatum were processed for tyrosine hydroxylase immunocytochemistry and developed with the avidin-biotin-peroxidase method (Vectastain, ABC Kit from Vec tor). Briefly, tissue sections of rat brain were treated with 0.05% saponin, followed by methanol and hydro gen peroxide, and finally normal horse serum. The sec tions were incubated overnight at 4°C with an anti-TH monoclonal antibody (Sigma), at a dilution 1:200. The peroxidase reaction was visualized with 0.05% diaminobenzidine and 0.01% hydrogen peroxide.
Cell Counts and Statistics
TH-positive neurons were counted in the ipsilateral striatum in six sections per animal and in four animals per condition, at a x250 magnification in a Zeiss-Jenalumar microscope. The total number of cells was calcu lated according to the volume of the graft: approx. 0.06 mm 3 . For statistical evaluation, data were subjected to one-way analysis of variance (ANOVA) and DMS post hoc test.
RESULTS
All studies were carried out in 6-OHDA-lesioned ani mals. The extent of the lesion was assessed in each ani mal by TH immunostaining. All animals included in the study showed almost complete loss of TH+ cells in the ipsilateral substantia nigra.
Viability of FMC Suspensions Before Grafting
Because FMCs are known to survive poorly after preparation of cell suspensions, we first examined whether preincubation of FMCs with neurotrophic fac tors known to promote the survival of dopaminergic neurons could prevent the loss of TH+ cells. Preincuba tion of FMCs at a concentration of 100,000 cells/pl in DMEM at 37°C for 6 h resulted in a decrease in the cell viability from 85% to 60%. In contrast, preincubation of FMCs in the same medium with NT-3 or GDNF (at 50 ng/ml) for 6 h maintained the viability of mesencephalic cell suspensions at about 85% (Fig. 1) .
Survival of Dopaminergic Cells After Preincubation With Neurotrophins and Grafting
Next, we tested whether preincubation of FMCs with NT-3 or GDNF enhanced the survival of TH+ cells in vivo, 1 week after intrastriatal grafting. Pretreatment with NT-3 or GDNF (at 50 ng/ml) increased the num bers of TH+ cells more than fourfold, compared to
FMCs preincubated without the factor (Figs. 2 and 3) ,
suggesting an early neuronal survival promoting effect of NT-3 and GDNF on TH+ cells grafted in the host striatum.
Survival of Dopaminergic Cells Co-Grafted With Transfected Fibroblasts
To examine whether constantly delivered NT-3 or FMCs alone (Fig. 4) . All the measures were performed 1 week after grafting, when only small tumors and focal damage were caused by the fibroblasts. Figure 5A shows the appearance of an implant of FMCs plus fibroblasts, 1 week after intrastriatal grafting. The survival of dopa minergic cells was much higher in co-grafts with NT-3-producing fibroblasts. This effect was also observed when different ratios of FMCs and 3T3 cells were cografted ( Table 1) The expression of both NT-3 (38) and its receptor, trkC (30) , is high during fetal development (between E14 and El6) but reduced in the adult brain. NT-3 is expressed in many brain areas, including the mesen cephalon and striatum, during the perinatal period (32) . NT-3 immunoreactivity has been detected both in glia and neuronal populations of developing substantia nigra (58) , and it has been shown to increase the survival of ventral mesencephalic dopaminergic neurons in primary cultures (27) . Our data also suggest that NT-3 is a sur vival factor for embryonic dopaminergic neurons in vivo, because preincubation of immature dopaminergic cells with NT-3, or direct supply of NT-3 to grafted FMCs in vivo, enhances the survival of TH+ cells in the host brain.
In addition, GDNF was initially characterized by its ability to promote the survival of mesencephalic dopa minergic neurons in vitro (37) , and more recently, it was reported to reduce the apoptosis of dopaminergic neu rons (14) . Because GDNF is also expressed in the devel oping striatum and mesencephalon (49, 52, 54) , and be cause its receptors, the proto-oncogene c-ret and the coreceptor GFRocl, are present in developing nigral neu rons (54, 55, 57) , it has been suggested that GDNF plays a trophic role in the developing nigrostriatal system. In the adult brain, GDNF mRNA is expressed at low levels both in the substantia nigra and in the striatum (5,47), suggesting a possible local and target-derived role of GDNF in the support of striatal and dopaminergic neu rons. Interestingly, mechanical injury increases GDNF expression in the striatum (36) , and administration of GDNF in vivo protects striatal neurons (41) . Moreover, the degeneration of nigrostriatal dopaminergic neurons can also be prevented in vivo by direct injection of GDNF protein (20, 45, 52) , adenovirus-mediated GDNF gene transfer (7,9,13,39), or cell-mediated delivery of GDNF (1,41).
Our results show that treatment of FMCs with NT-3 or GDNF prior to or during grafting enhanced the sur vival of dopaminergic neurons in the striatum. Indeed, the exposure of FMCs to trophic factors maintains in vitro their viability at least 6 h (Fig. 1) , and the in vivo survival of the dopaminergic cells, 1 week after grafting into the brain, was fourfold higher than that of non-preincubated cells (Fig. 2) . That indicates that prior treat ment of a cell suspension at early stages with trophic factors is crucial for the late survival of these cells.
Although both neurotrophic factors were beneficial, surprisingly, continuous administration of NT-3 in vivo was more effective than GDNF in maintaining the sur vival of dopaminergic neurons after grafting. Many studies have examined the beneficial effects of pretreat ment or treatment of FMCs with neurotrophic factors in vivo. Coadministration of GDNF and FMCs (3, 19, 50) or administration of GDNF in the vicinity of the intra striatal (19, 43, 46, 48) Sections were taken 7 days after grafting and were counterstained with hematoxylin. Scale bars = 100 um. 
